BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34971845)

  • 1. Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions.
    Macy E; Pandya S; Sheikh J; Burnette A; Shi JM; Chung J; Gin N; Crawford W; Zhang J
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):827-836. PubMed ID: 34971845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(4):125-129. PubMed ID: 33507892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.
    Patel GB; Chhiba KD; Chen MM; Guo A; Watts MM; Cullen J; Bochner BS; Grammer LC; Greenberger PA; Saltoun CA; Stevens WW; Kuang FL; Peters AT
    Allergy Asthma Proc; 2021 Nov; 42(6):515-521. PubMed ID: 34871159
    [No Abstract]   [Full Text] [Related]  

  • 5. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
    Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
    JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.
    Al-Obaydi S; Hennrikus E; Mohammad N; Lehman EB; Thakur A; Al-Shaikhly T
    PLoS One; 2022; 17(8):e0272691. PubMed ID: 35930586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.
    Kaplan B; Farzan S; Coscia G; Rosenthal DW; McInerney A; Jongco AM; Ponda P; Bonagura VR
    Ann Allergy Asthma Immunol; 2022 Feb; 128(2):161-168.e1. PubMed ID: 34699968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study.
    Xu S; Hong V; Sy LS; Bruxvoort KJ; Lewin B; Han B; Holmquist KJ; Qian L
    JMIR Public Health Surveill; 2023 Oct; 9():e46318. PubMed ID: 37792452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
    Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
    Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risk Factors of Immediate Hypersensitivity Reactions and Immunization Stress-Related Responses With COVID-19 mRNA Vaccine.
    Imai K; Tanaka F; Kawano S; Esaki K; Arakawa J; Nishiyama T; Seno S; Hatanaka K; Sugiura T; Kodama Y; Yamada S; Iwamoto S; Takeshima S; Abe N; Kamae C; Aono S; Ito T; Yamamoto T; Mizuguchi Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2667-2676.e10. PubMed ID: 35953016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
    Johnston MS; Galan A; Watsky KL; Little AJ
    JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults.
    Simone A; Herald J; Chen A; Nayak R; Shen YA; Lee MS
    Int J Cardiol; 2022 Oct; 365():41-43. PubMed ID: 35870635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
    J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Zhou ZH; Cortese MM; Fang JL; Wood R; Hummell DS; Risma KA; Norton AE; KuKuruga M; Kirshner S; Rabin RL; Agarabi C; Staat MA; Halasa N; Ware RE; Stahl A; McMahon M; Browning P; Maniatis P; Bolcen S; Edwards KM; Su JR; Dharmarajan S; Forshee R; Broder KR; Anderson S; Kozlowski S
    Vaccine; 2023 Jun; 41(28):4183-4189. PubMed ID: 37244808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination.
    Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG
    JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
    Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
    JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.